COMMUNIQUÉS West-GlobeNewswire

-
Teleflex Announces Tenth Anniversary of GuideLiner® Catheter Product Line
25/09/2019 -
Acarix carries out a rights issue of approximately SEK 51.8 million to finance an increased market expansion
25/09/2019 -
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
25/09/2019 -
Sequana Medical Announces 2019 Half Year Results and Year-to-date Business Update
25/09/2019 -
Sequana Medical Announces First Patient Enrolled in North American alfapump® Pivotal Study (POSEIDON)
25/09/2019 -
ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2019 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON SEPTEMBER 30, 2019
25/09/2019 -
Align Technology Further Advances Digital Dentistry in China With the Launch of the iTero Element 2 Scanner
25/09/2019 -
‘Better together’: Mental Health Commission of Canada and Canadian Mental Health Association announce strengthened collaboration
25/09/2019 -
« Mieux ensemble » : Renforcement de la collaboration entre la Commission de la santé mentale du Canada et l’Association canadienne pour la santé mentale
25/09/2019 -
Bone Bank Allografts Launches Global Sales Force Initiative
24/09/2019 -
Rockwell Medical, Inc. to Present at 2019 Cantor Global Healthcare Conference
24/09/2019 -
BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference
24/09/2019 -
Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
24/09/2019 -
SeaSpine® Announces Exclusive Development and Licensing Agreement with restor3D®
24/09/2019 -
Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin
24/09/2019 -
Colibri Heart Valve Receives a United States Patent Directed to a Replacement Heart Valve that Includes a Dry Valve Sutured to a Stent Member
24/09/2019 -
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
24/09/2019 -
Galapagos initiates Phase 1 trial for second Toledo compound
24/09/2019 -
Aeterna Zentaris Announces Closing of Approximately $5.0 Million Registered Direct Offering
24/09/2019
Pages